Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib vs Interferon Alpha-2a in Metastatic Renal Cell Carcinoma
NCT00117637Phase 2Completed
- Sponsor
- Bayer
- Start
- Jun 2005
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of sorafenib in renal cell carcinoma (RCC) (2 arms), sponsored by Bayer. Primary endpoint: Progression-free Survival Based on Independent Radiological Review for the First Intervention Period at 15 months. Started Jun 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00117637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117637.